Environmental and interoceptive cues are theorized to serve as 'signals' that motivate drug seeking and effects that may be augmented in the withdrawn state. Phasic dopamine release events are observed in the nucleus accumbens in response to such motivational salient stimuli and are thought to be necessary for drugassociated cues to trigger craving. We recently demonstrated how dopamine neurons encode stimuli conditioned to a negative event, as might occur during conditioned withdrawal, and stimuli predicting the avoidance of negative events, as might occur as an addict seeks out drugs to prevent withdrawal. In this review we first discuss how the subsecond dopamine release events might process conditioned withdrawal and drug seeking driven by negative reinforcement processes within the context of our dopamine data obtained during conditioned avoidance procedures. We next describe how the endocannabinoid system modulates phasic dopamine release events and how it might be harnessed to treat negative affective states in addiction. Specifically, we have demonstrated that endocannabinoids in the ventral tegmentum sculpt cue-induced accumbal surges in dopamine release and, therefore, may also be mobilized during drug withdrawal.
Introduction
Negative reinforcers, or events that increase the probability of behavioral actions resulting in the escape or avoidance of the particular event, are thought to play a prominent role in drug addiction. By recruiting neural pathways that process negative reinforcement, drug withdrawal is theorized to produce a negative emotional state-capable of driving persistent drug seeking (Childress et al., 1988; Koob et al., 1998) . While traditionally thought to be specific to drugs producing explicit somatic withdrawal symptoms, like opiates and alcohol, it is now recognized that all drugs of abuse produce some form of withdrawal.
Evidence for drug withdrawal
Drug withdrawal subsists in the absence of overt symptomatology (e.g., delirium tremens). For example, Wood and Lal (1987) used drug-discrimination to demonstrate that cocaine withdrawal is anxiogenic in nature. In their early behavioral pharmacological work, rats were trained to respond on one of two levers for food pellets under an FR10 reinforcement schedule after either receiving injections of the anxiogenic drug pentylenetetrazol or in the absence of any drug effect. They then tested to see whether the subjective effects of cocaine withdrawal generalized to those produced by pentylenetetrazol by treating rats with cocaine (20 mg/kg IP) every 8 h for 7 days, and then assessing lever selection after 8, 24, 96, 120 and 148 h of forced abstinence. They found that the withdrawal effects of cocaine generalized to the pentylenetetrazol stimulus effects, as animals increasingly selected the pentylenetetrazol-paired lever over the first 120 h of abstinence. While this study demonstrated that cocaine withdrawal is anxiogenic in nature, it is important to note that the reported withdrawal effects were devoid of somatic symptoms, such as: diarrhea, wet-dog shakes, weight loss, teeth chattering, tremors and convulsions (Wood and Lal, 1987) . Clinical studies corroborated the existence of a cocaine withdrawal syndrome, characterized by anxiety and sleep disturbances (Gawin, 1991; Watson et al., 1992) . Another classic example are the cannabinoids (e.g., marijuana), a drug class long thought to be devoid of withdrawal symptoms (Solomon and Corbit, 1974) . While spontaneous withdrawal symptoms are difficult to detect in experimental animals (Aceto et al., 1996 (Aceto et al., , 2001 , pronounced somatic withdrawal symptoms (e.g., wet dog shakes, paw tremors) are inducible by challenging dependent animals with a cannabinoid CB1 receptor antagonist (Aceto et al., 1995; Tsou et al., 1995) . Clinical studies further described a spontaneous cannabis-withdrawal syndrome, characterized by: anxiety, weight loss, restlessness, sleep problems, chills, depressed mood, physical discomfort, shakiness, and sweating (Budney and Hughes, 2006) . Together, these preclinical and clinical reports indicate that the majority of abused drugs are capable of producing some form of withdrawal. Abbreviations: 2AG, 2-arachidonoyl-glycerol; DA, dopamine; DG, Diacylglycerol; DGL, diacylglycerol lipase; GABA, gamma amino butyric acid; Glu, glutamate; mGluR, metabotropic glutamate receptor; NMDAR, N-methyl-D-Aspartate Receptor; PLC, phospholipase C.
